Experimental Hematology & Oncology

Experimental Hematology & Oncology accepted for inclusion in SCIE

We are delighted to announce that Experimental Hematology & Oncology has been accepted for inclusion in Science Citation Index Expanded (SCIE), a key database of Web of Science, published by Clarivate Analytics. Starting 2020, Experimental Hematology & Oncology will be published in the annual Journal Citation Reports, at which point it will receive the associated journal metrics, such as Immediacy Index, Eigenfactor Score, and Journal Impact Factor.

We would like to thank everyone for supporting Experimental Hematology & Oncology and contributing to this success.

Featured article: Bullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin

Bullous hemorrhagic dermatosis (BHD) is a systemic side-effect of low molecular weight heparin, characterized by multiple intra-epidermal hemorrhages distant from the site of injection. There have been several small case series and literature reviews on BHD, but none have captured a complete set of reported patients. Here, Dr. Russo et al. sought to describe a case of BHD with late diagnosis and completely summarize the existing English and Spanish literature with searches of Pubmed, Scopus, Ovid Embase and Ovid Medline.

Aims and scope

Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.

Experimental Hematology & Oncology is the companion journal of Journal of Hematology & Oncology.

Content type: Review
| 22 August 2019

Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer

Authors: Zhenbin Qiu, Zihao Chen, Chao Zhang and Wenzhao Zhong
Content type: Short report
| 22 August 2019

A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarker

Authors: Chunmei Wang and John K. Buolamwini
Content type: Research
| 21 August 2019

Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)

Authors: Camille Lobry, Ashish Bains, Leah B. Zamechek, Sherif Ibrahim, Iannis Aifantis and David J. Araten
Content type: Review
| 17 August 2019

Frontline therapies for untreated chronic lymphoid leukemia

Authors: Delong Liu and Juanjuan Zhao
Content type: Short report
| 6 August 2019

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

Authors: Alexandra Albertsson-Lindblad, Catja Freiburghaus, Mats Jerkeman and Sara Ek

Most recent articles RSS

View all articles

Content type: Review
| 24 November 2015

Breast cancer brain metastases: the last frontier

Authors: José Pablo Leone and Bernardo Amadeo Leone
Content type: Review
| 29 November 2012

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy

Authors: Kemeng Wang, Guoqing Wei and Delong Liu
Content type: Review
| 14 November 2013

Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies

Authors: Theresa L Schwartz, Harveshp Mogal, Christos Papageorgiou, Jula Veerapong and Eddy C Hsueh
Content type: Research
| 23 April 2012

Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis

Authors: Shamudheen M Rafiyath, Mohammad Rasul, Byung Lee, Guoqing Wei, Gurpreet Lamba and Delong Liu
Content type: Review
| 2 May 2017

The development of bispecific antibodies and their applications in tumor immune escape

Authors: Xiaolong Zhang, Yuanyuan Yang, Dongmei Fan and Dongsheng Xiong

Most accessed articles RSS

View all articles

Editors-in-Chief

Kongming Wu, Tongji Medical College
Delong Liu, New York Medical College
Zihai Li, Medical University of South Carolina

Editor's quote

"Like our companion journal, Journal of Hematology & Oncology, Experimental Hematology & Oncology publishes on all aspects of hematology and oncology, which are closely intertwined and rapidly evolving fields. Experimental Hematology & Oncology also emphasizes basic and translational research, as well as patient-oriented research and clinical trials with ‘negative’ or preliminary results. The journal is an international platform for sharing findings in these areas and adheres to fast turnaround times."

Delong Liu

Latest Tweets

Experimental Hematology & Oncology